Until recently, there has been no amyloid-targeting treatment available for Alzheimer's disease. We imagine a future where providers have the tools needed to identify, diagnose, select the right treatment, and monitor and visualize treatment response. A future where a strong provider network collaborates with patients and their families to identify signs of Alzheimer’s – even before symptoms begin.
With a unique, integrated cassette-based design and GMP-quality components, FASTlab 2 New Edition enables regulatory reliability & compliance in small-scale tracer production.
With a unique, integrated cassette-based design and GMP-quality components, FASTlab 2 New Edition enables regulatory reliability & compliance in small-scale tracer production.